Market closed
Castle Biosciences/CSTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Ticker
CSTL
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
703
Website
CSTL Metrics
BasicAdvanced
$814M
Market cap
-
P/E ratio
-$0.12
EPS
0.93
Beta
-
Dividend rate
Price and volume
Market cap
$814M
Beta
0.93
52-week high
$30.93
52-week low
$12.07
Average daily volume
323K
Financial strength
Current ratio
8.121
Quick ratio
7.748
Long term debt to equity
5.654
Total debt to equity
5.943
Interest coverage (TTM)
-54.71%
Management effectiveness
Return on assets (TTM)
-2.16%
Return on equity (TTM)
-0.77%
Valuation
Price to revenue (TTM)
2.781
Price to book
1.92
Price to tangible book (TTM)
2.61
Price to free cash flow (TTM)
39.725
Growth
Revenue change (TTM)
71.67%
Earnings per share change (TTM)
-96.52%
3-year revenue growth (CAGR)
54.43%
3-year earnings per share growth (CAGR)
-51.02%
What the Analysts think about CSTL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
CSTL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CSTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CSTL News
AllArticlesVideos
New Data at ASTRO 2024 Shows Castle Biosciences' DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
Business Wire·1 week ago
Castle Biosciences: Inflection Into Profitability
Seeking Alpha·2 months ago
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $814M as of October 08, 2024.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 0 as of October 08, 2024.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of October 08, 2024.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.